Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Total Non-Current Liabilities (2020 - 2025)

Arcutis Biotherapeutics has reported Total Non-Current Liabilities over the past 6 years, most recently at $243.1 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $243.1 million for Q4 2025, up 27.41% from a year ago — trailing twelve months through Dec 2025 was $243.1 million (up 27.41% YoY), and the annual figure for FY2025 was $243.1 million, up 27.41%.
  • Total Non-Current Liabilities for Q4 2025 was $243.1 million at Arcutis Biotherapeutics, up from $212.5 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for ARQT hit a ceiling of $280.3 million in Q3 2024 and a floor of $18.4 million in Q2 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $212.5 million (2025), compared with a mean of $174.7 million.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 892.99% in 2022 and later dropped 24.25% in 2024.
  • Arcutis Biotherapeutics' Total Non-Current Liabilities stood at $110.4 million in 2021, then soared by 117.01% to $239.7 million in 2022, then grew by 5.07% to $251.8 million in 2023, then decreased by 24.25% to $190.8 million in 2024, then rose by 27.41% to $243.1 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $243.1 million (Q4 2025), $212.5 million (Q3 2025), and $213.1 million (Q2 2025) per Business Quant data.